ACE2 and COVID-19: ACE inhibitors, angiotensin receptor blockers (ARBs), and emerging ACE2/Ang-(1–7)–targeted strategies aim to restore RAAS balance in diabetic patients at risk of COVID-19–related cardiac complications.